S 1407 119th Congress
ABC Safe Drug Act
A bill to ban the use of Federal funds for the purchase of drugs manufactured in the People's Republic of China, and for other purposes.
Official Title as Introduced Congress.gov
Open official Congress.gov recordSource-linked procedural record
Bill journey
This is a chronology, not a progress score. Politically.com does not classify stages or infer what comes next. Records sharing a date are grouped because not every source field supplies a time.
Congress.gov Recently refreshed
U.S. Senate XML Latest available (refresh delayed)
-
Introduction Congress.gov
Introduced
Introduced in the Senate.
Open bill recordOfficial action Congress.gov
Read twice and referred to the Committee on Finance.
Open bill recordOfficial action Congress.gov
Introduced in Senate
Open bill recordText version Congress.gov
Introduced in Senate
A dated text-version record is available.
Open text record
View the complete bill journey as an accessible table
| Date and time | Record | Official detail | Source |
|---|---|---|---|
| IntroductionIntroduced | Introduced in the Senate. | Congress.gov | |
| Official actionRead twice and referred to the Committee on Finance. | No additional detail supplied.IntroReferral · Senate | Congress.gov | |
| Official actionIntroduced in Senate | No additional detail supplied.IntroReferral · Library of Congress · Code 10000 | Congress.gov | |
| Text versionIntroduced in Senate | A dated text-version record is available. | Congress.gov |
House roll calls join only on matching Congress, legislation type, and number. Senate roll calls join only on matching source-supplied document type and number, not question text. Committee and related-measure relationships have no date in their relationship records and therefore are counted above but never placed on the chronology.
Congressional Research Service
CRS summary
Anyone But China Safe Drug Act or the ABC Safe Drug ActThis bill restricts federal health care programs from purchasing drugs with active ingredients manufactured in China and provides tax incentives for the purchase of certain pharmaceutical and device manufacturing property for use in the United States.The bill phases in restrictions on federal health care programs’ purchase of drugs. By January 1, 2030, federal health care programs may not purchase any drug that contains active ingredients from China or countries that do not meet the health and safety standards of the Food and Drug Administration. The Department of Health and Human Services may issue a waiver for an agency or program that is unable to meet this requirement; this waiver authority expires in 2031. The bill also requires all drugs to be labeled with the country of origin of each active ingredient in the drug. Drugs that are not labeled with this information are deemed misbranded.Finally, the bill allows 100% tax expensing for qualified pharmaceutical and medical device manufacturing property placed in service between 2025 and 2030. Qualified pharmaceutical and medical device manufacturing property is any tangible property placed in service in the United States as part of the construction or expansion of property for the manufacture of drugs or devices.
Official documents
Text versions
- Introduced in SenateApr 10, 2025